New York, May 29, 2026, 16:01 (EDT)
- Enveric finished the session at $2.30 on Nasdaq, slipping 0.86%. Market cap is about $8.5 million.
- The latest update posted by the company is still the May 19 preclinical safety release on EB-003.
- The company’s Q1 filing said current cash won’t cover 12 months of operating needs.
Enveric Biosciences shares fell Friday, with the stock hanging near recent lows. The small-cap biotech had little news, and investors are watching for progress with its main drug candidate before human trials.
The stock closed at $2.30 on Nasdaq, slipping 0.86%. Shares traded in a range of $2.20 to $2.41. Market cap stood near $8.47 million. The 52-week span is $1.71 to $17.64, showing the wide swings in the stock.
Enveric remains preclinical. Its last press release, dated May 19, talked about EB-003, the main neuroplastogen candidate. There was nothing about revenue, a new product approval or fresh funding.
Enveric Biosciences is working on EB-003 for neuropsychiatric conditions such as depression, anxiety and PTSD. The company said its lead neuroplastogen didn’t show photoreactive potential in early lab tests for phototoxicity—how a drug might get dangerous if hit by ultraviolet light.
“The demonstration of limited potential for phototoxicity enhances the favorable safety profile of EB-003,” Chief Executive Joseph Tucker said in a May 19 release. Tucker said Enveric is moving toward first-in-human Phase 1 trials. Enveric Biosciences
Enveric said it’s working to take EB-003 to an IND filing, which it needs before starting human trials in the U.S. In the Q1 update, CEO Tucker said Enveric is still “laser focused” on pushing the drug to the IND stage and into clinical testing.
Balance sheet details are less straightforward. Enveric posted a net loss of $1.63 million in the first quarter, better than the $2.18 million loss from the same quarter last year. Research and development costs dropped to around $346,000, down from about $746,000 a year ago.
Enveric CFO Kevin Coveney said in a May 15 update the company had about $10.3 million in cash at that time, following a private placement and warrant exercises in April. That cash should fund EB-003 preclinical work, the planned IND filing, and operations into the first quarter of fiscal 2027, the company said.
Enveric’s latest 10-Q included a going-concern warning, raising real questions about whether it can keep going another year without new funding or another break. The company said it doesn’t have enough cash on hand to cover its operating needs for the next 12 months.
The sector has stayed choppy, but trading picked up. Reuters said this month a U.S. executive order to speed up psychedelic-drug development has drawn fresh investor interest. Researchers told Reuters new treatments are still likely far off.
Compass Pathways, AtaiBeckley, and GH Research all moved up late Friday, trading with other stocks linked to psychedelic and neuropsychiatric drugs. The SPDR S&P Biotech ETF saw only a small gain. Enveric, by contrast, still trades as a name driven by its own funding and execution rather than a broad sector move.
Enveric faces a clear risk if it can’t get funding on terms it likes, according to the filing. The biotech might need to slow, push back or reduce its R&D if it doesn’t secure capital. Even with an IND filing, early-stage data doesn’t mean the drug will prove safe or effective in people. The stock trades at less than $10 million in market cap, so any hiccup, expensive capital raise or trial delay could hit the shares hard.
